Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MIDATECH PHARMA PLC. We currently have 57 research reports from 4 professional analysts.
|20Jan17 11:05||RNS||Second Price Monitoring Extn|
|20Jan17 11:00||RNS||Price Monitoring Extension|
|20Jan17 07:00||RNS||Trading Update|
|20Dec16 12:56||RNS||Director/PDMR Shareholding|
|15Dec16 16:31||RNS||Holding(s) in Company|
|22Nov16 07:00||RNS||Midatech receives upfront on Emergex vaccine deal|
|02Nov16 12:57||RNS||Holding(s) in Company|
Frequency of research reports
Research reports on
MIDATECH PHARMA PLC
MIDATECH PHARMA PLC
PG: Growth Prospects in Healthcare
26 Jan 17
We expect the volatility of the last 3 months to continue, with macro events, particularly the uncertainty brought by President Trump and his focus on pharma pricing and dismantling the Affordable Care Act, likely to keep healthcare in the headlines for the wrong reasons. We believe the more highly valued larger stocks are likely to struggle to break out to new trading levels, but note there remains good value within the smaller end of the sector for stockpickers, with company specific events likely to drive some stocks well ahead of the crowd.
N+1 Singer - Morning Song 20-01-2017
20 Jan 17
Abzena (ABZA LN) ThioBridge™ licensing deal demonstrates technology leadership | Halfords Group (HFD LN) Positive lead indicators + FX mitigation progress | Midatech Pharma (MTPH LN) FY trading update: revenue ahead of estimates | MySale Group (MYSL LN) Strong progress in H1; positive momentum bodes well for H2 | PCI-PAL (PCIP LN) H1 revenue slightly ahead, CFO stepping down | Raven Russia Ltd (RUS LN) A step forward | SDL (SDL LN) Transformation progressing well | Synthomer (SYNT LN) Positive trading update and forecast upgrade
N+1 Singer - Midatech Pharma - FY trading update: revenue ahead of estimates
20 Jan 17
Midatech’s FY trading update indicates revenue for the period of c. £9.0m, ahead of our £8.0m estimate. The £16.7m (gross) capital raise announced in October allows Midatech to accelerate development of its key programmes. We continue to expect data from a gold nanoparticle (GNP) enabled Phase I diabetes vaccine trial in 2017, followed by the start of clinical trials in brain and liver cancer by early 2018. In addition, Q-Octreotide in our view represents a significant near-term licensing opportunity. We reiterate our Buy recommendation.
Panmure Morning Note 20-01-2017
20 Jan 17
Midatech Pharma’s trading update for the 12 months to 31 December 2016 reports ‘good progress across the group’ with total reported revenues expected to be circa £9.0m (2015: £1.4m). On this basis, the revenue performance for the year comes in-line with our top-of-the-range forecast (and is circa +4.9% vs consensus) and provides excellent validation of the group’s commercial capabilities and the potential of its US commercial presence. We believe the news flow, particularly as we look towards updates on Q-Octreotide in the coming months, reflects management’s ambitions and capabilities in building an international specialty pharmaceutical business, and we consider the wider business well-set to continue on its planned growth profile. Buy.
Panmure Morning Note 22-11-2016
22 Nov 16
Midatech’s previously-announced programme (04 January 2016) in conjunction with Emergex (infectious disease) has today crystallised an upfront technology access fee and option payment of £450,000 to Midatech. We think today’s news represents a strong validating point within the relationship between the two companies and consider the programme sits in a highly complementary manner alongside Midatech’s programmes in immunotherapy, auto-immune disease and immuno-oncology. We remain Buyers and repeat our 297p target price.
Panmure Morning Note 15-11-2016
15 Nov 16
While Midatech’s liver cancer programme has been perhaps overshadowed by the strength of news flow generated by other areas within its development portfolio (e.g. recent progress with Q-Octreotide MTD201, OpsiSporin and MTX110/MTX111 for the treatment of DIPG), this morning’s announcement of the selection of a wholly-owned candidate compound MTR104 sees the liver programme continue on track with previously announced timelines. This should see MTR104 taken into a formal IND-enabling programme during 2017, followed by human studies planned for 2018. An area of significant unmet clinical need, we consider this another key programme with Midatech’s development stable. We repeat our Buy recommendation.
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
Panmure Morning Note 15-02-2017
15 Feb 17
With the early January trading update having prompted us to upgrade forecasts, today’s interim results show how the group’s focus on areas such as product development and international sales are translating through to growth in both the top and bottom-line. The consistency of delivery is what impresses us, reflecting the maturity of the management team and the clarity of the longterm vision. We repeat our Buy recommendation.
Panmure Morning Note 20-02-2017
20 Feb 17
Chi-Med has announced the initiation of a Phase II study of savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China. This is a disease where patients are usually diagnosed by normal pathology (i.e. not via molecular diagnostics methods) but given that 20-30% of PSC patient show c-Met gene amplification this potentially represents a very rich patient pool for savolitinib as a highly selective and potent oral c-Met inhibitor. The continued strength of Chi-Med’s clinical momentum is further demonstrated by today’s news and we consider this represents further upside potential against our existing investment case. We repeat our Buy recommendation.